-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RY0/Le4vfEE00JAMzAa8OcWm+sVsK1bOuEEnqgXTeiXixfrL8pXox6RE4LBVSTb8
 Ip74dmFEXlZKH7CxULHpaQ==

<SEC-DOCUMENT>0000950133-04-003440.txt : 20040908
<SEC-HEADER>0000950133-04-003440.hdr.sgml : 20040908
<ACCEPTANCE-DATETIME>20040908162652
ACCESSION NUMBER:		0000950133-04-003440
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20040908
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040908
DATE AS OF CHANGE:		20040908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MARTEK BIOSCIENCES CORP
		CENTRAL INDEX KEY:			0000892025
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521399362
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22354
		FILM NUMBER:		041020949

	BUSINESS ADDRESS:	
		STREET 1:		6480 DOBBIN RD
		CITY:			COLUMBIA
		STATE:			MD
		ZIP:			21045
		BUSINESS PHONE:		4107400081

	MAIL ADDRESS:	
		STREET 1:		6480 DOBBIN RD
		CITY:			COLUMBIA
		STATE:			MD
		ZIP:			21045
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w01887e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt">SECURITIES AND EXCHANGE COMMISSION



<P align="center" style="font-size: 10pt">Washington, D.C. 20549



<P align="center" style="font-size: 10pt"><B>FORM 8-K</B>



<P align="center" style="font-size: 10pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt">Pursuant to Section&nbsp;13 or 15(d)<BR>
of the Securities Exchange Act of 1934



<P align="center" style="font-size: 10pt">Date of Report (Date of earliest event reported): September&nbsp;8, 2004

<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center">MARTEK BIOSCIENCES CORPORATION<HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(Exact name of registrant as specified in its charter)</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center">Delaware<HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">0-22354<HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">52-1399362<HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of<BR>
incorporation or organization)&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File<BR>
Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center">6480 Dobbin Road, Columbia Maryland<HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">21045<HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: (410)&nbsp;740-0081
<P>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">&nbsp;<HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(Former name or former address, if changed since last report)&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp; Written communications pursuant to Rule&nbsp;425 under the
Securities Act (17 CFR 230.425)


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the
Exchange Act (17 CFR 240.14a-12)


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))


<P align="center" style="font-size: 10pt">-1-
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>INFORMATION TO BE INCLUDED IN THE REPORT</B>



<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02. Results of Operations and Financial Condition.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;8, 2004, Martek issued a press release announcing its
financial results for the fiscal quarter ended July&nbsp;31, 2004. A copy of
Martek&#146;s press release is furnished as Exhibit&nbsp;99.1 to this press release.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information in this Current Report on Form 8-K, including Exhibit&nbsp;No.
99.1 hereto, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to liability
of that section. The information in this Current Report shall not be
incorporated by reference into any filing or other document pursuant to the
Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing or document.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>



<P align="left" style="font-size: 10pt"><B>(c)&nbsp;Exhibits</B>


<P align="left" style="font-size: 10pt">The following is furnished as an Exhibit to this Current Report on Form 8-K.


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit No.</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description of Exhibit</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated September&nbsp;8, 2004 issued by Martek Biosciences
Corporation (Furnished pursuant to Item&nbsp;2.02).</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">-2-
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Martek Biosciences Corporation</B></TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="left" nowrap valign="top">Date: September 8, 2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ George P. Barker<BR>
<HR size="1" noshade width="75%">
George P. Barker<BR>
Senior Vice President, General<BR>
Counsel and Secretary</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">-3-
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w01887exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="right" style="font-size: 10pt">EXHIBIT 99.1

<P>
<IMG src="w01887martek.gif">
<P>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="75%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="59%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;<BR>
<B>FOR IMMEDIATE RELEASE</B><BR>
&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact:<BR>
<B>&nbsp;</B><BR>
&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pete Buzy<BR>
Chief Financial Officer<BR>
(410)&nbsp;740-0081</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center"><B>MARTEK ANNOUNCES THIRD QUARTER FINANCIAL RESULTS</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>REVENUES OVER $47 MILLION; EARNINGS OF $5 MILLION</B></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt">COLUMBIA, MD &#150; September&nbsp;8, 2004: Martek Biosciences Corporation (NASDAQ:MATK)
today announced its financial results for the third quarter and nine months
ended July&nbsp;31, 2004. For the third quarter of 2004 (3rd Qtr 04), revenues of
$47.3&nbsp;million were achieved, up from $29.1&nbsp;million for the 3rd Qtr 03, and for
the nine months ended July&nbsp;31, 2004 (04 YTD), revenues of $124.8&nbsp;million were
achieved, up from $76.1&nbsp;million for 03 YTD. For the 3rd Qtr 04, Martek earned
net income of $5.0&nbsp;million, or $0.16 per diluted share, compared to net income
of $4.6&nbsp;million or $0.16 per diluted share in the 3rd Qtr 03. For 04 YTD,
Martek earned net income of $11.8&nbsp;million, or $0.38 per diluted share, compared
to net income of $9.8&nbsp;million or $0.37 per diluted share for 03 YTD.


<P align="left" style="font-size: 10pt">&#147;Martek has been able to overcome production problems created by the fire at
DSM&#146;s U.S. facility and still achieve a 63% quarterly revenue growth. New
production capacity coming on-line as well as increased efficiencies and
economies of scale should allow rapid growth to continue with increasing gross
profit margins in the coming quarters. &#147; stated Henry &#147;Pete&#148; Linsert, Jr.,
Chief Executive Officer of Martek.



<P align="center" style="font-size: 10pt"><B><U>3rd Qtr Consolidated Financial Results</U></B>


<P align="left" style="font-size: 10pt">Total revenues for the 3rd Qtr 04 were $47.3&nbsp;million, an increase of $18.2
million or 63% over the 3rd Qtr 03. A significant portion of this increase is
due to higher sales of nutritional products to the Company&#146;s infant formula
licensees (For a history of the Company&#146;s nutritional product sales by quarter
see the chart at <U>http://www.martekbio.com/images/corporatePages/VU79P.gif</U>).
Approximately 90% of Martek&#146;s 3rd Qtr 04 nutritional product sales were
generated from sales of docosahexaenoic acid (DHA)&nbsp;and arachidonic acid (ARA)
to four of the Company&#146;s infant formula licensees: Mead Johnson, Wyeth, Abbott
Laboratories and Nestle. Supplemented term infant formulas manufactured by
three of these companies were introduced in the U.S. in 2002, and Nestle
launched a supplemented formula in the U.S. in 2003. Also included in Martek&#146;s
3rd quarter revenues were $3.3&nbsp;million related to contract manufacturing
revenues generated by the former FermPro business in Kingstree, SC, which was
acquired in September&nbsp;2003. Significant revenue growth is projected by the
Company for fiscal years 2005 and 2006. In order to maximize the profitability
of these revenues and ensure a sufficient infrastructure exists to support this
growth, Martek has recently expanded both the research and development and
selling, general and administrative areas within the Company. See below for
additional discussion.


<P align="left" style="font-size: 10pt">Consistent with the prior two quarters of fiscal 2004, during the 3rd quarter,
the Company satisfied as much customer demand as possible, while, at times,
sacrificing cost efficiencies. As such, gross profit margin on total revenues
decreased to 38% during the 3rd Qtr 04, from 42% for the 3rd Qtr 03, but
improved from the gross profit margin of 35% realized in the 2nd Qtr 04. The
decrease from 3rd Qtr 03 resulted from the Company&#146;s continued use of air
freight in connection with ARA shipments from Europe and internal production
inefficiencies in connection with the commencement of DHA manufacturing at the
Kingstree plant. The gross profit margin for the current quarter was also
impacted by an increase in the Company&#146;s overall cost of ARA due to the decline
in the U.S. dollar against the euro; however, such impact was largely offset by
the benefits of certain DHA production improvements recently developed and an
insurance receipt by Martek of approximately $1&nbsp;million associated with the
fire incident at DSM. We expect our gross profit margins in the 4th Qtr 04 to
continue to reflect the benefits of the newly implemented production methods
and expect the impact of the negative factors noted above to be greatly
mitigated by the end of Martek&#146;s fiscal year. Gross profit margin for the 3rd
Qtr 04 compared to the 3rd Qtr 03 also includes the impact of $3.3&nbsp;million of
lower margin contract manufacturing revenues related to the former FermPro
business.


<P align="left" style="font-size: 10pt">Research and development expenses increased by $1.5&nbsp;million or 42% in the 3rd
Qtr 04 compared to the 3rd Qtr 03. The increase is primarily the result of the
additional resources directed toward our continuing efforts to lower our DHA
production cost by increasing our fermentation production yields and developing
new downstream processing techniques. In addition,



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">costs were incurred in
connection with the development of DHA products for the food and beverage
industry and exploration of new DHA applications as well as in the long-term
development of plant-based DHA under the collaboration agreement with
SemBioSys.


<P align="left" style="font-size: 10pt">Selling, general and administrative expenses increased by $2.8&nbsp;million or 67%
during the 3rd Qtr 04 over the 3rd Qtr 03. Of this increase, approximately
$800,000 relates to our Kingstree, SC plant acquired in September&nbsp;2003, for
which an administrative infrastructure has been added to support the new
facility and its expansion. The remaining increase is primarily due to
additional personnel and insurance costs required to accelerate and manage the
Company&#146;s overall growth. Specifically, the Company has increased staffing in
its business development, food and beverage sales and marketing and finance
departments.


<P align="left" style="font-size: 10pt">Other operating expenses totaled $1.6&nbsp;million and $200,000 in the 3rd Qtr 04
and 3rd Qtr 03, respectively. These expenditures related primarily to
production start-up costs associated with the expansion at our Kingstree, SC
facility and qualifications of certain third-party manufacturers as well as
expenses related to the Winchester wastewater treatment matter. We anticipate
continuing to incur these types of expenses for the remainder of fiscal 2004.


<P align="left" style="font-size: 10pt">Net income of $5.0&nbsp;million, or $0.16 per share on a diluted basis, was realized
in the 3rd Qtr 04, compared to net income of $4.6&nbsp;million, or $0.16 per share
on a diluted basis for the 3rd Qtr 03.



<P align="center" style="font-size: 10pt"><B><U>Year-to-date Consolidated Financial Results</U></B>


<P align="left" style="font-size: 10pt">Total revenues for 04 YTD were $124.8&nbsp;million, an increase of $48.7&nbsp;million or
64% over 03 YTD, due primarily to higher sales of nutritional products to the
Company&#146;s infant formula licensees. Gross profit margin decreased to 37% for 04
YTD, from 41% for 03 YTD, primarily due to higher freight costs and unfavorable
exchange rate fluctuations, both related to our ARA costs from DSM. Research
and development expenses increased by $4.0&nbsp;million or 42% in 04 YTD compared to
03 YTD due to the commencement of various development projects. Selling,
general and administrative expenses increased by $7.4&nbsp;million or 66% in 04 YTD
over 03 YTD due primarily to increased personnel and insurance costs required
to support the Company&#146;s growth as well as the addition of our new Kingstree,
SC facility. Other operating expenses, as described above, of $2.7&nbsp;million and
$1.3&nbsp;million, were incurred in 04 YTD and 03 YTD, respectively. Net income of
$11.8&nbsp;million, or $0.38 per diluted share was realized for 04 YTD, compared to
net income of $9.8&nbsp;million, or $0.37 per diluted share for 03 YTD.


<P align="left" style="font-size: 10pt">The Company used cash flow from operations of $2.0&nbsp;million for 04 YTD. This use
of cash was primarily the result of the continued buildup of DHA inventory. Due
to a shortage of ARA, this additional DHA inventory could not be blended with
ARA for sales to infant formula manufacturers during the 3rd Qtr 04, but now
well positions Martek to respond to the expected demand for DHA-only
applications such as the pregnancy and lactation market and provides the
Company with certain protection from future unanticipated DHA inventory
shortfalls. Capital expenditures for 04 YTD were $153.1&nbsp;million, the majority
of which were related to the expansion of the newly acquired Kingstree, SC
facility to increase output of the Company&#146;s nutritional oils. The Company
generated cash flow from financing activities of $103&nbsp;million primarily due to
borrowings under the Company&#146;s revolving credit facility and proceeds from the
exercise of stock options and the issuance of common stock. At the end of the
quarter, Martek had approximately $37.7&nbsp;million in cash, cash equivalents and
short-term investments, a decrease of $59.2&nbsp;million from October&nbsp;31, 2003. In
order to meet its capital needs, the Company may raise capital in the public or
private markets, in the form of debt or equity, in the coming quarters.


<P align="left" style="font-size: 10pt">As noted above, the Company continues to add manufacturing capacity and
generally expand its business to meet market demand for its products. In order
to support this expansion, Martek has increased overall staffing levels. As of
July&nbsp;31, 2004, the Company employed 518 full-time employees, of which 153 have
been hired during the first nine months of fiscal 2004, including 126 whose
focus relates to production or research and development activities.



<P align="center" style="font-size: 10pt"><B><U>Recent Highlights</U></B>



<P align="left" style="font-size: 10pt"><B>Recent events impacting Martek include:</B>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="right">&#149;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD><I>Production and Supply of Nutritional Oils </I>&#150; Since fiscal 2003, the
demand for our nutritional oils for use in infant formula products has
significantly exceeded production capacity. These shortfalls have
resulted from an acceleration of such demand over what our customers had
projected coupled with a shortage of ARA production capacity from DSM
that began in the first quarter of fiscal 2004. Martek has historically
produced the DHA component at its Winchester, KY facility and purchased
the ARA component from DSM at its Capua, Italy plant. The Company is in
the process of a significant production expansion including additional
ARA production from DSM. Our expansion initiatives include the
following:</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" nowrap align="right">&#186;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD><I>Expansion of Kingstree production facility </I>&#150; During the 3rd
Qtr 04, Martek continued its extensive expansion at its Kingstree,
SC location for the fermentation and processing of the Company&#146;s
nutritional oils. The overall expansion is expected to cost $170 -
$180&nbsp;million when complete. Certain components of the initial phase
of the expansion commenced commercial operation during the 3rd Qtr
04 with other components of this phase, including the fermentation
area, expected to commence commercial operation and generate
products available for sale in the 4th Qtr 04. Upon completion of
the second expansion phase in 2nd Qtr 05, Martek&#146;s DHA production
capacity should triple over current levels.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" nowrap align="right">&#186;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD><I>Production at DSM&#146;s Belvidere Facility </I>&#150; In May&nbsp;2004, a fire
occurred at the Belvidere, New Jersey manufacturing plant of DSM
causing a temporary shutdown of the ARA production line. In June
2004, DSM restarted the production line at the Belvidere facility.
Since that time, Belvidere has continued to increase its monthly
output of ARA. It is anticipated that by the end of fiscal 2004,
Martek will be receiving approximately 40% of its ARA from DSM&#146;s
Belvidere facility with that percentage expected to grow in the
future.</TD>
</TR>

</TABLE>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="right">&#149;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD><I>New toddler &#147;follow-on&#148; product </I>&#150; Two infant
      formula manufacturers
have launched a new toddler product supplemented with Martek&#146;s DHA and
ARA. The new lines are formulated to meet the nutritional needs of
children from nine to twenty-four months of age, and are the first of
their kind in the U.S. to be fortified with DHA and ARA.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="right">&#149;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD><I>New Vice President of Marketing &#151; </I>In August&nbsp;2004, David Ross joined
Martek as Vice President of Marketing and Sales. Prior to joining
Martek, Mr.&nbsp;Ross spent 25&nbsp;years at Merck &#038; Co., most recently serving as
Vice President, Marketing in the Merck Vaccine Division since 1999. In
this position, he was responsible for the worldwide marketing and
development of portfolio vaccine products which generated annual
revenues totaling approximately $1&nbsp;billion. Mr.&nbsp;Ross received his M.S.
in Industrial Administration from Purdue University and his B.S. degree
in Microbiology and Public Health from Michigan State University.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="right">&#149;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD><I>DHA Alzheimer&#146;s Animal Study &#150; </I>In September&nbsp;2004, the results of an
animal study conducted by the UCLA School of Medicine of the effects of
Martek&#146;s DHA on the advancement of Alzheimer&#146;s disease in laboratory
mice were published in the journal Neuron. The study found that a diet
rich in DHA significantly lessened the memory loss and cell damage
caused by Alzheimer&#146;s disease in laboratory mice. These findings add to
the evidence that DHA may play a role in countering the progression of
Alzheimer&#146;s disease in humans.</TD>
</TR>

</TABLE>

 <P>
<P align="center" style="font-size: 10pt"><B><U>Investor Conference Call Webcast</U></B>


<P align="left" style="font-size: 10pt">Investors may listen to Martek&#146;s senior management discuss the Company&#146;s
quarterly earnings and other current business issues on Wednesday, September&nbsp;8,
2004 at 4:45 p.m. EDT by accessing Martek&#146;s website at <U>www.martekbio.com</U>,
selecting the &#147;Investors&#148; tab, choosing &#147;Live Webcast&#148; and following the
related instructions. The webcast will be available for replay through the
close of business on September&nbsp;22, 2004.



<P align="center" style="font-size: 10pt"><B><U>General</U></B>


<P align="left" style="font-size: 10pt">Sections of this release contain forward-looking statements concerning, among
other things: (1)&nbsp;expectations regarding future revenue growth, product
introductions, growth in nutritional product sales, production expansion,
margin and productivity improvements, applications and potential
collaborations; (2)&nbsp;expectations regarding sales to infant formula licensees;
(3)&nbsp;expectations regarding future efficiencies in manufacturing processes and
the costs of production of nutritional oils and purchase of third-party
manufactured oils; and (4)&nbsp;expectations regarding production capacity and the
cost of expansion. These statements are based upon numerous assumptions which
Martek cannot control and involve risks and uncertainties that could cause
actual results to differ. These statements should be understood in light of the
risk factors set forth above and in the Company&#146;s filings with the Securities
and Exchange Commission, including, but not limited to our Form 10-K for the
fiscal year ended October&nbsp;31, 2003 and other filed reports on Form 10-Q and
Form 8-K.



<P align="center" style="font-size: 10pt"><B><U>About Martek</U></B>


<P align="left" style="font-size: 10pt">Martek Biosciences Corporation develops, manufactures and sells products from
microalgae. The Company&#146;s products include: (1)&nbsp;specialty, nutritional oils for
infant formula that aid in the development of the eyes and central nervous
system in newborns; (2)&nbsp;nutritional supplements and food ingredients that may
play a beneficial role in promoting mental and cardiovascular health throughout
life; and (3)&nbsp;new, powerful fluorescent markers for diagnostics, rapid
miniaturized screening, and gene and protein detection.



<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B>MARTEK BIOSCIENCES CORPORATION</B><BR>
<BR>
Summary Consolidated Financial Information<BR>
(Unaudited &#151; $ in thousands, except share and per share data)



<P align="left" style="font-size: 10pt"><B>Consolidated Statements of Income Data</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Three months ended July 31,</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Nine months ended July 31,</B><HR size="1" noshade></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Revenues:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Product sales:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Nutritional product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">43,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">28,748</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">112,331</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">75,183</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Fluorescent detection product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">561</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">754</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
  <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV>
  </TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Total product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,040</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">114,140</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75,937</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Contract manufacturing sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,350</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Other revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">107</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">342</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">170</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">124,832</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76,107</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Costs and expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cost of product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,264</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,017</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70,042</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,001</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cost of contract manufacturing sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,912</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,549</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,932</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,660</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,628</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,872</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,316</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Restructuring reversal</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(250</TD>
    <TD nowrap>)</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Other operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,587</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">247</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,691</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,313</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
  <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV>
  </TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD height="18"><DIV style="margin-left:10px; text-indent:-10px">Total costs and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,567</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,861</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">113,692</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">67,008</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Income from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,770</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,254</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,140</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,099</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Other income, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">241</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">349</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">651</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">656</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Income before income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,011</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,603</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,791</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,755</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Income tax expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">5,011</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,603</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">11,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,755</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Basic earnings per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Diluted earnings per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.38</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Shares used in computing basic earnings per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,270,301</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,050,781</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28,936,660</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,793,415</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Shares used in computing diluted earnings per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,168,113</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,399,615</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,105,821</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,544,481</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>Consolidated Balance Sheet Data</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="74%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>July 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>October 31,</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>&nbsp;</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>(Audited)</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cash, cash equivalents and short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">37,723</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">96,971</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,751</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41,373</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Property, plant and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">236,916</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88,314</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Goodwill and other long-term assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82,259</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68,865</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
  <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV>
  </TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">418,649</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">295,523</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Liabilities and stockholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">36,659</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">32,126</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Non-current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97,845</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,433</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">284,145</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">243,964</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">418,649</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">295,523</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><B>Consolidated Cash Flow Data</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="74%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Nine Months Ended July 31,</B><HR size="1" noshade></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">11,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,755</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Non-cash items</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,908</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,971</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Changes in operating assets and liabilities, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(19,654</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(2,401</TD>
    <TD nowrap>)</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Net cash (used in)/ provided by operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(1,985</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,325</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Investing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Purchase of property, plant and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(153,093</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(20,459</TD>
    <TD nowrap>)</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Cash impact of purchase transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(231</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">940</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Capitalization of intangible and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(6,967</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(908</TD>
    <TD nowrap>)</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net cash used in investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(160,291</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(20,427</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Proceeds from the exercise of warrants and options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,222</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,881</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Proceeds from the issuance of common stock, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,281</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83,341</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Borrowings under revolving credit facility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Repayments of notes payable and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(2,475</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(107</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
  <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV>
  </TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="right"><HR size="1" noshade>
&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Net cash provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103,028</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94,115</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Net change in cash, cash equivalents and short-term
investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(59,248</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,013</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cash, cash equivalents and short-term investments, beg of
period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96,971</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,419</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cash, cash equivalents short-term investments, end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">37,723</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">107,432</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">5
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w01887martek.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w01887martek.gif
M1TE&.#=A00).`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````00).`(0````1$1$B(B(S,S-$1$15555F9F9W=W>(B(B9F9FJJJJ[N[O,
MS,S=W=WN[N[___\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,$__#)26MUS=G-N_]@*(YD:9YHJJYLZ[YP+,]TO2Z*
MH1=\?RP:FW!(+!J/R*1RR6P>%81"-,JC2@FZA7/+[7J_X+!XC'0L#-:>0:K;
M^;3DN'Q.K]OO^$EC3258"3\4#%*$"'F'B(F*BXR("SV$A&L)&PB0!'"-FIN<
MG9Z?(U!^A`-3F!8."80)#:"NK["QLF(+HWV1#(((!WZL#P[`$@NYL\7&Q\C)
M(+4#57Y3`Q2/!`,(N:D(!`H/#;P$K<KAXN/DBPU3D>AP@U((&@J\/%JU:N7V
M]_CY30X&I5=]!*ZA*>`N%34>!UIELU7@@+Z'$"-*1#'M2A4IVQA$,<#`##I`
M$O\&IODVL:3)DQ#/$;JE[0&#9NX2C&I&\-=`FI$,H=S)LV>Q1RNM;!/5\)(4
MA_PNCB3ILZG3IXK66"ST(-O*'J,*V+2([B(EJ&##B@4#]"H6!PJF7HK2<2#7
MM5K'RIU+EX@JLP<<:#0%J4?'`U@O]I4"KJ[APXA/``88<.]5I0ZA3'VFM,"`
M3(DS:]XL`>N4!?2"#GX@&6"DM5\YJUXMUP%C5I0/1J$9T,$_4M!Z-`/)NK?O
MIK:QYDWW%F'5KA_[3G'X&TR0YM"]!&]F8(_IV5@;/-K]UI_E*@,<XE!`OKSY
M\^:?FT"+OCUZ]3L9G$=`7X>```$(1-^_)3AAF1_Q%87_(6@P)*!1(!$`P((,
M-NB@@\PI]N"$$Q;&DX(4-J@??QPJX1H/"M##T'?H:,<=0]SAM)LAP+28@0,#
M9,A@`"@X(".#0&3P8C`^8="B`P%,N&&'1!JQA@(J#99&0P\`)IAR@X'808SY
MR;B-"0DL6(",Q!A&85Q%ABG$+@XLEM55-+%"BE$6\:';E1LH&,`",@IP@@`+
M,B`C9G3A^>"08@8JPP(-R!3E8`:D<JA@5$C%`WP4Q&AGC!G"*8(""^;%)6)!
M_BGHIX.N<:(5W!50)E=G9D4J#Q[(^0"=&=)(@I_`[,FID*#FZH*CBU+ASJ+*
M2265I19(*H&?%%KX098`&,#-_Z:'?:GKM"I(=EME422@D3-_K,FHLA6X2IJ,
M@'[0J08V9LCG7,AJ2.V[)Q1HEF@+W&7@O)=$R(&Q$MP([@;,QM4`M)PD0-\N
M;>B$1*<.E@OOPQYL9PHZ_F!RUVZQ63:3;I"&"X"L#S`K+0A^PI$NA>LRPK"[
M2;3+H,,0QVR!,]@2PH`JR3UV9@&I30F`G1(`*6/'TBP8C00#9]CE)BXO"+,0
M)SL(ILQ47_#/Q+-A$IILJ*KJ+`CB2H"`C%-O0&DF43^8\B)-`_"T$&V_777,
MAHX4"9(!$M=5`?\6^S,%0E,(\@9ZNDU!TA0NK4G<2JS\\MR04U`:91@[:TG%
M*/*E>/\'84L@\H0]5[`E`)BE[>#:(6#00`9'K$[T`XRKL'K?'<0>>>365L9#
M`PR(!,D!OD!1W0C\3F!Z@P)T7'BYB$^X>0?R'7#?A`$(T!`04]XG@/;;3[\@
M?&FY7(U+#)1?^(,#F*_^ZRXAL/V#UFO[P<C2=%\]]]O??S_[M[.65F4T81$?
M-F(I>/#/8X/SG(Q"UYD\7<!6RZ`4``HPC%]P@P$'<!P!&%@5`QS@@VT#0&$6
M@"?\4.]&,E(8X#*HI8Y8L%`2'``')>`XIUE@#P?P8`X[)8`/YO"#B>I?A[K!
MDAY<R7S@FJ$'BF>\.EF@<$<[',$XT("5H2YP#?I:!T;W('3_C4T`5Z*0``YV
M`,$=[(R*<\#8%A0`)7+Q8RFKH>$BUJD$'%"(^P&*J@I@`-2EH',3**.Z/$8Z
M5$"0BHZ+X@;:1JP*&"!9#L!37I!&(47:K@.1;%#9*@"K+%K@DA48A--HA\<P
M]>XQ!+DC\?[V1!DI,FE`JT#S'O2\":SQ=+4#G0?>V*`&X$F%59R0ON0H-Y<X
MKI$5F)`6:3BA32KP8\@L):BT\S^L#*\%@)P`+QW4I=&IL(F#[(`@'?1-"K2M
MG!38II8`4$X&N&R9L,-5!X*)2P^TS4+$?"*E^";-?JJ`B5+,T(;2E;P-S)*;
M'CA?+W/Y('W-+$.Q?&("Y/=)>7)`_XY^?`"%`)5/"JQQ3OX,*0JRJ<U-K1&=
MOS@D!WJG/020\IP>>"2%E/@!4'J40M$,6H;,:=$$2!">(@TJ"``:T"\)+:*R
MG"(+VN90T>T4!3:=0`CQ0]6JFO"IS'R05LJ$/J%Z%6P?VZ6,!(G2E(:3!,!H
M@`+.2!\YEO4!,O445"V:U"_Y\`"[V,5=]:I7O%*`F.ZLI"J_VD^B%NU&":QK
MXD*!@`&L+`"E\(,<FYI."KW57'25W%E3D,\$R/%GM21L4$D:J1O1]'@X6@8O
MQ[@YF'8@K@ZB:4TS.P%,H6RI\O1EAF0K6FD:]K""8]]!&Q3:5TEP00)`G6LY
MH$X`%'>V<O]MY6U7($<P97*FO24L:2F`H0E=%K4+0ETGB6M/[XJU0IRE[00^
MF],1;!1PS04`9;/K6U9ZX',.XM]P&53+\3)(D8LT[Q8I--B*1M<"MZPG"130
MLXY2`+\-&D"!Z1NS[?)4JR``;R$W,$Z6=6"R,4U6"J*ZW@FU=P.8(L!SHFI;
MZI&2PG/[;05:/*,7/TMI%U7O!&#;H+<V=\)_U;$$%,J@$X<R2$NK+@=H["`!
M/!?&,K/PA1GD3$-NMK3.6VF&?"SBN<(/Q?Q<0")'H%N'.OB&(60GE/$HXQD[
MR,8W7BR'Q<@G?OR,J1,HGU,G!&2I4L\"=`H`.(@,@#L6KJEGCE/_AH"ZYFG]
MZ$=R>C2/_+8@1OOHTOM=D`+2^J-?I%D`.@!,I<<%OP3D```2_A&/^;LC#(Q@
MU4[KB!D>&8"EB9)!`B#E.3Y&C$?'K=/&:U%WM=JB1E-KV"B<8P5N"2D-)YN_
MW#BNX!*RXQ22^MD-XFW0TIS%CBW`L0SJXX^T<X`8#0!.SK9HAY-M9&/SYV8,
MCK>IYRUO!J_-WDNN][PGRF]^QUO?SX&'"8.$G_"D[!$#1[4[D#91>>^[X?2>
M=X%SD'""$\"E'VC`Y=A8/?R`VAH6\/?#&1QQ?`]9W_LFN;SA[.Z6KZ?8&0;V
M$M`%\Q)(VN4XS[G.=\[SGOO\YT`/NM"'_T[THN<\`7=-.EZ5OG2F._V#??5A
MU/?J]*E3_>E)M[K4E:[UIC.]ZU@/^]6S7O6R?_WI5@>[V<E^]K9SW>UL?SO<
MMSYWNL?][F/'.]37KO>]R_WO??=ZW@=O][YW_?!\+SSA_7Y7HSO^\9"/O.0G
M3_G*6_[RGZ@7-8+@&FT\&00:`;#Q]@(:!'!DR)>-6+M=4"\&[R*C0\`!YO'X
M;0!\Q1(;3AWK%HG4"L0('-\+V7Q#@/0B("``SZE7$O0R`8/-7HA(^AD&$O#(
M3&@''-J9AP;&AC;L/<"Q+@&-!134BBIJA7>8J6#0"/4<!F#/#%UR/](J*'\]
M>/\7A+(_?&PD>O_]"X/]\P"`ZJ%^X7=!$T"`6S)DXK=^Z`(:P'!_SP<JFZ8@
MU&=G<#``B0)JO[`E\```IU80,M0`&`@[R7,`2`(?,3)1;+&!A18RIL(`M?8`
M?*,1T:8`,,@`N\8-3E9%F[8E'#$`=B*"K-!#,I@0?!0R2!((MF1?TI`^YT`)
M66(`GL4*^($DK.)..'B$F-)'\I4`N?9(+D$`M08,"E*#UJ%&[*01R!>!N;)I
M>A(`SE)]GC.$0+,E79(E6C`VP/-!WQ<`!5!0XR="QU)(CY0!\B4!0$B"1+@E
M&H`]"?A("(!T!"*(!H!\6=(*.$@G4FAZ:K0]`2%%`-8*B2B#(J0G^M+_#"$A
M0N`'5Z1#)PK3#0PP-AJ0@*E(BJV`*1/E7$TBB&SX*=@CAJFH!7JR#0)P-(RX
MA$"0)<20"]L#(X!86N"`)[FP)1D0`,PA`/IA#21D&RWH$@]0AF,##EKP2+-(
M(Y<H`39H>\*0"KQ3$](@:+;D$'_8&<BG)SUC/2%A)V4D`1ED!FI&0UI11N58
M;2$CB.%XCH78BX)2+X2B<:]B"3:H$FNU0=U`04'P$B88,ASA4GM0`.73$(6A
M%X#A>@>0"QI7`-NP!Z6G`<"S`"P2B?*Q.H"1C-80D2.I<7TD?+&H`;US,UJ`
M=/4"+AA$'@9S>PG@DK?(,X5A/58(#@A@@]2F*@H4Q0.1.#X^I2VQ2$$AHRW6
;H"A(8@G:II!B^04:.)9F*1'T\'EG*0$1```[
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
